Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency
- Conditions
- Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency
- Interventions
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Medicure
- Target Recruit Count
- 15
- Registration Number
- NCT04706013
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Lucile Packard Children's Hospital, Palo Alto, California, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
Pharmacokinetic Evaluation of Tirofiban Using a Single High-Dose Bolus In Subjects With Varying Degrees of Renal Function
- First Posted Date
- 2013-01-11
- Last Posted Date
- 2014-03-27
- Lead Sponsor
- Medicure
- Target Recruit Count
- 25
- Registration Number
- NCT01766154
- Locations
- 🇺🇸
Avail Clinical Research, LLC, DeLand, Florida, United States
Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention
- Conditions
- Myocardial InfarctionAcute Coronary SyndromesUnstable Angina
- Interventions
- First Posted Date
- 2012-01-31
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- Medicure
- Target Recruit Count
- 535
- Registration Number
- NCT01522417
- Locations
- 🇺🇸
Doylestown Hospital, Doylestown, Pennsylvania, United States
🇺🇸Redmond Regional Medical Center, Rome, Georgia, United States
🇺🇸Osceola Regional Medical Center, Kissimmee, Florida, United States
Aggrastat Truncated Length Against Standard Therapies in Percutaneous Coronary Intervention
- Conditions
- Myocardial InfarctionUnstable AnginaPercutaneous Coronary InterventionAcute Coronary Syndromes
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-11-22
- Last Posted Date
- 2018-03-13
- Lead Sponsor
- Medicure
- Registration Number
- NCT01245725
Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia
- First Posted Date
- 2009-06-10
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Medicure
- Target Recruit Count
- 53
- Registration Number
- NCT00917293
- Locations
- 🇨🇦
Centre for Addiction and Mental Health, Toronto, Ontario, Canada
🇨🇦Windsor Regional Hospital, Windsor, Ontario, Canada
🇨🇦Vancouver Island Health Authority, Victoria, British Columbia, Canada
A Safety and Efficacy Study to Confirm the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG
- Conditions
- Coronary Artery Bypass Graft SurgeryMyocardial IschemiaReperfusion Injury
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2007-11-16
- Lead Sponsor
- Medicure
- Target Recruit Count
- 3000
- Registration Number
- NCT00402506
- Locations
- 🇨🇦
Montreal Heart Institute, Montreal, Quebec, Canada
🇺🇸Duke Clinical Research Institute, Durham, North Carolina, United States
MATCHED (MC-1 and ACE Therapeutic Combination for Hypertensive Diabetics)
- Conditions
- Diabetes Mellitus Type 2HypertensionMetabolic Syndrome
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2006-10-31
- Lead Sponsor
- Medicure
- Target Recruit Count
- 160
- Registration Number
- NCT00157729
- Locations
- 🇨🇦
Centre Hospitalier Université Laval, Sainte-Foy, Quebec, Canada
MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery)
- Conditions
- Coronary Artery Bypass Graft SurgeryMyocardial IschemiaReperfusion InjuryMyocardial Revascularization
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2006-10-31
- Lead Sponsor
- Medicure
- Target Recruit Count
- 900
- Registration Number
- NCT00157716
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇨🇦Montreal Heart Institute, Montreal, Quebec, Canada